anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Customary sweetened healthy line of sport drinks. Utility and methods of manufacturing are disclosed. The products&#39; line is designed to benefit healthy consumers beginning of age 5 Years old and up. The liquid drinks include sterilized milk or Lactaid 100%, organic or natural type derived from grass fed cows given no growth hormones or antibiotic and rich in Omega-3 and conjugated linoleic acid (CLA). The milk is mixed with a portion of water having the pH between 6.5 and 8.5. Each sport drink further includes water soluble dietary fiber and a bouquet of proprietary essential oils or botanical extracts blend known for its natural benefits against many human ailments and tend to maintain the health of blood, kidney and digestive tract. The products&#39; liquid solutions exhibit an average specific gravity range between 0.75 to 1.150. Additional ingredients such as natural preservatives, emulsifiers, proteins, vitamins and minerals may also be included to further enhance the aesthetics or authenticity of the presented line of intended healthy drinks. The manufacturing methods are simple but articulate.
The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer&#39;s Disease, Idiopathic Dementia, and Traumatic Brain Injury. The methods of the present invention include the perispinal administration of etanercept. For the purposes of this patent “perispinal” is to be considered as referring to “perispinal extrathecal;” therefore direct intrathecal administration is excluded. Perispinal administration leads to enhanced delivery of etanercept to the brain in a therapeutically effective amount, via the vertebral venous system and/or the cerebrospinal fluid. Delivery of etanercept to the brain utilizing the methods of the present invention includes the use of the vertebral venous system to deliver etanercept to the brain via retrograde venous flow. Physical maneuvers are used to enhance delivery of etanercept to the brain via this route.
The invention relates to substituted isoindolon derivatives of formula (I), wherein R&lt;1&gt;, R&lt;2&gt;, R&lt;3&gt;, R&lt;4&gt;, R&lt;5&gt;, R&lt;6&gt; and R&lt;7&gt; have the meanings cited in the description. Said derivatives represent valuable active substances in medicaments for the therapy and prophylaxis of diseases, e.g. cardiovascular diseases such a hypertension, angina pectoris, heart failures, thrombosis or atherosclerosis. The compounds of formula (I) are capable of modulating endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of pathological states associated with disorders of the cGMP metabolism. The invention also relates to a method for the production of compounds of formula (I), their use in the therapy and prophylaxis of the above-mentioned pathological states and in the production of medicaments for such states. The invention further relates to pharmaceutical preparations containing the compounds of formula (I).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antioxidant and a hypertension inhibitor which comprise a fermentation treated product of Zizania latifolia.  &lt;P&gt;SOLUTION: The antioxidant and the hypertension inhibitor comprise a fermentation treated product of Zizania latifolia. Compared to an extract of Zizania latifoia, the fermentation treated product of Zizania latifolia has a superior anti-oxidant action and angiotensin converting enzyme inhibition effects and has exhibited hypertension inhibition effects. The fermentation treated product of Zizania latifolia has also exhibited an excellent antihypertensive action on rats. A food or a drug comprising the same has exhibited safe and excellent hypertension inhibition effects.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Provided are: a compound having an excellent effect of controlling external parasitic organisms such as ticks and fleas; a crystal of an isoxazoline compound represented by formula (I), said crystal being composed of a single diastereomer of the isoxazoline compound; and an external parasitic organism control agent for animals, said external parasitic organism control agent comprising the aforesaid compound as the active ingredient. According to the present invention, a stable preparation of the aforesaid compound can be obtained by crystallizing the same as a single diastereomer. [In formula (I): X represents a halogen atom, etc.; n, which represents the number of the substituent(s) X(s), is an integer of 0-5; X&#39; represents a halogen atom; m, which represents the number of the substituent(s) X&#39;(s), is an integer of 0-6; R 1  represents a C 1-6  haloalkyl group; R 2  represents a hydrogen atom, etc.; R 3  represents a hydrogen atom, a substituted or unsubstituted C 1-6  alkyl group, etc.; and p, which represents the repeat number of methylene group(s) in the parentheses, is an integer of 1 or 2.]
PROBLEM TO BE SOLVED: To obtain a new antimicrobial substance capable of exhibiting antimicrobial action even on disease-causing microorganisms against which the existing antimicrobial substance is not entirely effective. SOLUTION: This antimicrobial substance BE-65932 is a compound expressed by the formula or its pharmaceutically acceptable salt, and has the following physicochemical properties: (1) being white powder or solid; (2) having the molecular formula: C24 H31 O11 N5 ; (3) having a specific rotation [α]&lt;20&gt; D+71.4 (c 1.0, MeOH); (4) capability of easily dissolving in an organic solvent (e.g. methanol, dimethyl sulfoxide (DMSO), or the like) and water, and being difficult to dissolve in chloroform; (5) having basicity; (6) being positive in color reactions of test of readily carbonizable substances and phosphomolybdic acid reaction, or the like. The substance of the formula is obtained by incubating microorganisms belonging to Streptomyces and capable of producing the compound of the formula (pref. streptomyces sp.  A 65932 or its variant) and by collecting the compound of the formula from cultures, and is useful as an antimicrobial agent against disease caused by various kinds of microorganisms.
It is now recognized that oxidative stress, an imbalance of antioxidant system against free radicals and reactive oxygen species in ow body, is the basic pathophysiology of many diseases including life-threatening heart disease, stroke, certain cancers, Alzheimer&#39;s and age related dementia. Boosting the antioxidant system at specific vulnerable biochemical pathway sites will therefore help to prevent, delay or treat these diseases - an observation confirmed in many studies around the world. There is no existing patent covering 3 different classes of antioxidant ingredients namely Vitamin, (Vit. C, E.), essential minerals (Selenium) and phytonutrients (proanthocyanidins) and co-factors (Vit. B 12, folic Acid) formulated at optimal doses with minimal side effects. In addition, the composition of Ultra-Vit. Plus is based on the synergistic actions in the newly discovered endogenous antioxidant biochemical system in the body.    Ultra-Vit. Plus formula will contribute immensely in the technical field of integrated preventive medicine and basic understanding of mechanism of action in the biotechnology of antioxidant systems.      The Ultra-Vit. Plus formula applying for patent consist of Vit C 500 mg (as calcium ascorbate) Vit E 400 I.U. (as mixed Vit. E Tocopherals, and Tocotrienols) Folic Acid 0.5mg Vit. B 12 500mcg Selenium 90mcs. Proanthocyanidins 90mg (mcg) (Equal mixture of maritime Pine Bark Extract and Grape Seed Extract.) In addition, it is applying for patent use for prevention and treatment of oxidative stress and related diseases.
NEW MATERIAL:HS-2 having the following physical and chemical properties. Property: strongly hydroscopic white-light brown rubbery substance. Molecular formula: C24H48O11S2. Elemental analysis (%): C 47.04 H 8.55. Melting point: not showing a clear melting point. Color reaction: positive in Bromocresol Green reaction, iodine reaction and anisaldehyde reaction and negative in 2,4- dinitrophenylhydrazine reaction, FeCl3 reaction and Dragendorff&#39;s reaction. Solubility: soluble in alkali water, slightly soluble in neutral water and insoluble in methanol and chloroform, etc. USE:A vasodilator and antihypertensive agent. PREPARATION:A bacterium such as Actinoplanes ferrugineus ATCC 29868 belonging to the genus Actinoplanes is cultured at 20-40 deg.C at neutral pH for 3-15 days.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for treatment of cancer of rectum. For this purpose during operation in presacral space till its complete filling-in introduced is medication - &#34;hydrogel napkins with 5-fluoruracyl and sodium alginate &#34;Coletex -5-ftur&#34; with addition of 50 mg of carboplatin. Two drainages of different diameter are installed into presacral space. After that, peritonisation with uninterrupted suture is carried out tightly. On 5-6 day after operation hydrogel &#34;Coletex-gel-DNA&#34; is introduced through drainages into presacral space until it is completely filled. ^ EFFECT: method ensures reduction of frequency of local recurrences and metastases after cancer of rectum surgery due to efficient intraoperative local chemical therapy in combination with reparative therapy after operation. ^ 1 ex
1,146,848. Substituted bicyclo-[2,2,2]-octanes. E. I. DU PONT DE NEMOURS &amp; CO. 1 June, 1966 [2 June, 1965; 28 June, 1965], No. 24463/66. Heading C2C. The invention comprises (1) compounds of the formulµ (wherein R and R 1  are H, C 1-4  alkyl or allyl; and Y is H, CH 3 , C 2 H 5 , Cl, Br, F, CF 3 , OH, OCH 3  or OC 2 H 5 ) and acid-addition salts thereof; and (2) a process for preparing a 4- pyridyl or substituted pyridyl-bicyclo-(2,2,2)- octane-1-amine in which a 4-pyridyl-bicyclo- (2,2,2)-oct-2-ene-1-carboxylic acid or ester thereof is reduced by shaking in an atmosphere of hydrogen using a platinum catalyst, the ester, if used, is hydrolysed to the corresponding octane carboxylic acid, and this is then converted to the required amine by reaction with sodium azide in concentrated sulphuric acid and chloroform; or the amine is prepared by reaction of the ester with hydrazine hydrate, then with sodium nitrite in dilute acetic acid and finally heating under hydrolytic conditions, or by reaction with hydroxylamine and similar heating. The pyridine N-oxides are prepared at the ester stage by reaction with a peracid or peroxide, then conversion to the amine as described above. The amines may also be prepared by conversion of the esters to the amides and treatment of these with sodium hypohalites. The amines may be N-alkylated by standard procedures. The compounds of the invention may also be prepared by the synthetic methods indicated below. The compounds of the invention, which are stated to be anti-depressants, may be made up into pharmaceutical compositions with suitable carriers. Hard gelatine capsules, tablets and injection solutions containing 4-(4-pyridyl)- bicyclo-[2,2,2] -octane- 1-amine dihydrochloride and soft gelatine capsules containing the corresponding free base are described.
ABSTRACT         The specification describes and claims a paste-like preparation comprising (A) a paste-like base comprising a polyorganosiloxane and a water-soluble polymeric material which are preferably present in a ratio by weight from 3:6 to 6:3 and (B) an active ingredient.  The polyorganosiloxane is substantially linear and comprises predominantly R2SiO units and chain terminating units R&#39;R2Si01/2 where each R represents a lower alkyl group, a halogenated alkyl group 9 an alkenyl group or an aryl group and each R&#39; represents a group R or a hydroxyl group, and the polyorganosiloxane is a liquid or a gum at 25°C.  The water-soluble polymeric material may provide from 10 to 90%  by weight of the base and may be chosen from water-soluble polymers and copolymers of acrylic acid, methacrylic acid, acrylamide, cellulose derivatives and salts thereof, carboxymethylchitin, polyvinylpyrollidone, polyvinyl alcohol, starch derivatives, polyethylene oxide, gelatin, collagen and natural gums. The water-soluble polymeric material may be a particulate solid, the particles of which have a mean diameter of 2 to 100 micrometers.  The preparation may comprise up to 70% by weight of a paste adjusting component chosen from fatty materials.  The active ingredient may comprise for example a perfume, antiseptic or fertilizer or a drug, or quasi-drug, for example, a germicidal, antibiotic, anaesthetic, chemotherapeutic, vasodilator, expectorant, antianginal, hemostatic, gastrointestinal, antidiabetic, hormone or contraceptive agent.  The preparation is capable of adhering to wet surfaces such as mucosa and of releasing the active ingredient whilst adhered to the surface.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparations as ointment used for treatment of bacterial eczema, paraproctitis, hemorrhoid, burns, trophic ulcers and other sluggish wounds with external medicinal agents and to methods for preparing preparations also. The proposed preparation (ointment) comprises an antibacterial substance, anesthetic and stimulating agent for repairing (recovery) and it comprises additionally propolis spirituous solution, sea- buckthorn oil, Saint-John&#39;s-wort oil, celandine herb sap, vinylinum, lanolin, vaseline taken in the definite ratio of components. Invention provides the maximal curative effect of preparation. EFFECT: expanded assortment of spectrum of curative effect, valuable medicinal properties of preparation. 3 cl
A confectionary lip gloss product is described. The product includes a vessel with a hollow cavity and an edible fluid confectionary housed within the vessel. An applicator for applying the fluid confectionary to a user&#39;s lips can also be provided. A method of consuming a confectionary is also described. The method involves the steps of applying an edible fluid confectionary to lips of a user in a substantially even and uniform manner. Once applied, the user can lick the edible fluid confectionary from the lips and ingest it. A method of marketing a confectionary product is also described. The marketing method involves packaging an edible fluid confectionary in a vessel, selling the edible fluid confectionary in combination with an applicator; and instructing a user to apply the fluid confectionary to a user&#39;s lips using the applicator.
The invention is based on taking advantage of two effects of Q10 - the antioxidative one, i.e. the preventive one and the &#34;energizing&#34; one, i.e. the revitalizating and regenerating one. By adding Q10 to cosmetic pharmaceutical preparations, the increase in protection power against UV rays is achieved, as Q10 prevents the formation of free radicals or neutralizes them and at the same time, strengthens body cells to become more resistant to damages from UV rays and regenerate more quickly after   eventual damages. Besides, by adding Q10 to preparations for hair, scalp, lips, etc., such as ointments and creams for lips, shampoos, gels, and hair regenerators, which by themselves are not intended for the protection against sunrays, the application value of such products is increased also with regard to the purpose of protection and regeneration after the impact of UV rays, and also improved in general their preventive and regenerative acting against other harmful effects. Q10 is applicable for                                               alleviation or treatment of scalp problems such as dandruff, loss and greasing of hear and baldness. The use of Q10 is characterized in that it is applied as an additive to preparations for protection of exposed body parts against negative effects, preferentially negative effects of the sun or UV rays, wind, cold, heat and chemical substances. The preparations for protection of exposed body parts are characteristic in that they contain Q10 alone or together with other products applied for protection                                              against negative effects.
The invention discloses a premix auxiliary material. The premix auxiliary material comprises polyvinylpyrrolidone, glyceryl behenate, and a pharmaceutical adjuvant filler and a pharmaceutical adjuvant disintegrant, wherein the weight ratio of the filler, the disintegrant, the polyvinylpyrrolidone and the glyceryl behenate is (80-98.5):(10-0.5):(5-0.5):(5-0.5). The premix auxiliary material comprising the polyvinylpyrrolidone and the glyceryl behenate is good in fluidity, strong in compressibility and good in lubricating effect. The mixing uniformity, the medicine content, the tablet hardness, and the like would not change with prolongation of the total mixing time. The premix auxiliary material is prone to enlargement. Indexes comprising fluidity, the Carr&#39;s index, compressibility, friability, etc. of the premix auxiliary material provided by the invention are superior to corresponding indexes of auxiliary materials mixed physically. Uncontrollable factors of the technology are reduced, thus facilitating large-scale production. The premix auxiliary material can be used for direct compression of tablets or encapsulation of capsules.
An electronic system facilitates the clinician-patient encounter and serves as a single point of integration for all electronic health care information systems. A physician selects a diagnosis, which is converted from the physician&#39;s preferred terminology to a standard ICD diagnosis. The system then proposes a preferred treatment appropriate to the selected diagnosis. The physician can change any items of the proposed treatment plan, with changes being checked against payor rules, prior patient information and selected authorities&#39; guidelines. If a diagnosis or treatment element is not authorized by the payor for the selected diagnosis, the system notifies the physician, allowing changes or offering electronic request for payor authorization. Additionally, the system may indicate those diagnoses for which payor allows said elements, allowing the physician to choose a diagnosis that is consistent with the patient&#39;s symptoms and supports the desired treatment. Upon accepting a diagnostic and treatment plan, the plan elements are preferably carried out automatically. For example, payor authorizations are requested as necessary, prescriptions are transmitted to the patient&#39;s preferred pharmacy, laboratory tests are ordered, and tests, referrals, and appointments are scheduled electronically.
The invention relates to a traditional Chinese medicine composition for preventing and treating acute hemorrhoids and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6 parts of safflower, 6 parts of wine-processed rhubarb, 6 parts of szechuan lovage rhizome and 3 parts of honey-fried licorice root. The invention also comprises the application of the traditional Chinese medicine composition in preparing the medicine for preventing and treating acute hemorrhoids. Its advantages are: 1. according to the etiology and pathogenesis of acute haemorrhoids, the raw materials are selected according to symptoms, the weight parts of the raw materials are preferably selected, and the obtained formula can effectively relieve the clinical symptoms of patients. Fully embodies the traditional Chinese medicine treatment concept of &#39;preventing before illness and preventing illness&#39;. 2. The raw material medicines have wide sources, the preparation method is simple and convenient, the medicine can be prepared into a clinically acceptable preparation form according to the needs of patients, the acceptance of the patients is improved, and the medicine has good curative effect, strong practicability and good application prospect.
The embodiment of the application relates to the technical field of artificial intelligence, and discloses a recipe recommendation method, electronic equipment and a storage medium. Based on attribute information and input information of each recipe in the recall recipe list, a trained classification model is adopted to calculate the selection probability of each recipe so as to obtain an inference recipe list. And determining a recommended recipe list according to the recall recipe list and the reasoning recipe list. In this embodiment, the recalled recipe list is beneficial to the user&#39;s health. The list of inference recipes reflects the probability of user selection, i.e. preference bias. Therefore, the recommended recipe list can give consideration to health and personalized preference of the user, and is more reasonable.
Animal tissues containing Castle&#39;s intrinsic factor are extracted with water at a pH of from 2 to 4, and the aqueous extract is fractionated with a liquid organic precipitating agent consisting of an aliphatic monohydric alcohol or ketone having less than 5 carbon atoms to obtain as a precipitate an intrinsic factor concentrate of enhanced potency.  Hog duodenum or stomach tissue may be employed as the starting material, and it may be comminuted by hashing, or grinding; the frozen tissue may be ground in the presence of dry ice to prevent any loss of activity. The extraction may be carried out at below 15 DEG C.  To the filtered extract ethanol, methanol, acetone methyl ethyl ketone or other aliphatic monohydric alcohol or ketone having less than 5 carbon atoms may be added until its concentration in the extract is between 20 and 60 per cent by volume, the temperature being held below 0 DEG C., and the pH between 4 and 6. The precipitate containing the Castle&#39;s intrinsic factor may be separated by centrifuging and purified by solution in ice-cold water and lyophilization.  The pH adjustment for the extraction step may be made by addition of hydrochloric, sulphuric, phosphoric, lactic or citric acid and for the fractionation step by addition of sodium, potassium or calcium hydroxide or sodium or potassium carbonate or bicarbonate.  Detailed examples of the procedure are given.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for administering a medicament, a health food, or the like, to a companion animal.  &lt;P&gt;SOLUTION: This method utilizes the behavior that the companion animal licking its own body, then the medicament, the health food, or the like, is administered to the companion animal by applying or spraying them to the body surface of the companion animal. A brush, a swab or a splay is used as a method for applying or spraying. Thus, it is not hard to make the companion animal take the medicament, the health food, or the like. In addition, since the taken medicament is never vomited, it is easy to administer the medicament, the health food or the like to the companion animal.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain sustained releasing granules containing drugs in pores of the granules by impregnating porous calcium phosphate granules burned at a specific range of temperature and having a specific Ca/P ratio, porosity, specific surface area and pore diameter with a drug and drying. CONSTITUTION:Porous calcium phosphate-based compound granules burned at 200-1400 deg.C (preferably 700-1200 deg.C) and having 1.3-1.8Ca/P ratio, 0.1-70% porosity, 0.1-50m&lt;2&gt;/g specific surface area, 1nm-10mum pore diameter and 1mum-10mm granular diameter are impregnated with a drug and lyophilized to afford the objective sustained releasing granules. Sustained releasing effect of said granules is able to be controlled by varying granular diameter, porosity or specific surface area. The granules after administration are readily captured as harmless to an organism and has an excellent shadow-creating property. Besides, specific gravity is able to be controlled by coating with an organic polymeric compound (e.g. albumin) and able to be applied to a perivascular thrombolic treatment. Furthermore, hollow granules are used and drug is able to be contained in the vacant parts.